

Week of September 28 - October 2, 2015

## DEPARTMENT OF PSYCHIATRY & BEHAVIORAL NEUROSCIENCES



### Weekly Newsletter

#### In this Issue

Save the Date  
Farewell  
Lectures, Meetings, & Grand Rounds  
AHA Heart Walk  
Contact List  
Current Research

#### Save the Date!

11/7 AHA Annual Heart Walk  
11/18 Thanksgiving Potluck Luncheon  
12/12 Department Holiday Party at Dr. Currier's House

### Farewell for Dr. Gabriel de Erausquin

Please join us Friday October 30th at 2:00 pm in the 2nd floor education lecture room #232 to express our farewells and best wishes to Dr. Gabriel de Erausquin! Dr. de Erausquin has provided much educational, patient, and research experience, compassion, and knowledge to our department and the USF Morsani College of Medicine in his years with us.

### Resident Lectures

Thursday, October 1

PGY 1-4 & Child & Adolescent Psychiatry Residents

Please see the weekly didactic notice emails from the Education Office for scheduled topics and presenters

### Third Year Medical Students

Friday, October 2

7:00 - 8:00 AM Neurology in Psychiatry - Dr. Alfred Frontera

8:00 - 9:00 AM Sleep Disorders - Dr. Chetan Gandhi

9:00 - 10:00 AM Grand Rounds - Department of Neurology

10:00 - 11:00 AM Acute Stroke & ICH - Drs. Rose, Burgin, & Guerrero

11:00 AM - 12:00 PM Acute Stroke & ICH - Drs. Rose, Burgin, & Guerrero

### Grand Rounds

Thursday, October 1 - 12:00 pm noon

Topic: "Pharmacological Treatment of Addiction" by William Hervey, M.D.

Location: MH Outpatient Clinic (10770 N. 46th Street, Building E, Room 209)

### CONGRATULATIONS!

#### 2015 Best Doctor in America Recipients

Dr. Alvaro, Dr. Barnett, Dr. Bengston

Dr. Glenn Catalano, Dr. Marie Catalano, Dr. Cavitt

Dr. Gootam, Dr. Huska, Dr. Murphy

Dr. Phillips, Dr. Roth, Dr. Sanchez

Dr. Shaw, Dr. Stewart, Dr. Stock, Dr. Winston

Dr. Tan received a \$224,250 NIH Grant

Comprising only 5% of U.S. Doctors, recipients of the Best Doctor in America Award are selected based on their clinical and academic accomplishments. Dr. Tan received a NIH grant for his project titled "A flavonoid gamma-secretase modulator (GSM) reduces beta-amyloid and tau pathologies in the AD mice."

### AHA Heart Walk

Be sure to check your email for updates about our "Psych Will Hike" team for this year's American Heart Association annual Heart Walk. There is just over one month left to sign up. Friends and family are welcome. You can sign up and/or donate [here](#).

### Contact List

A contact list will be circulated via email shortly for internal use that details points-of-contact for common questions, concerns, and inquiries.

### Happy Birthday!

Gregory Sullivan (10/3)

### Current Research

#### Now Enrolling – Mild Alzheimer's Disease

This is a double-blind, placebo-controlled study to test the safety and effectiveness of an anti-amyloid antibody administered subcutaneously as a disease-modifying treatment in patients age 50 - 90 with mild AD. Stable dose of approved medications for AD will be permitted at study entry. Patients will undergo brain MRI exams for monitoring safety and response to study treatment. They will also undergo safety and cognitive testing. Patients must have a person with whom they are regular contact, who can accompany them to study visits.

Please call Kathy at (813) 974-7006 to make a referral.

Principal Investigator: Jean Fils, MD

#### Now Enrolling – Major Depressive Disorder Study for Adolescent Patients

This is a double-blind, placebo-and active -controlled study to test the safety and efficacy of Levomilnacipran ER treatment in adolescent patients age 12-17 with Major Depressive Disorder. In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran. Patients could be enrolled into the 10mg, 20mg, 40mg or placebo group. Patients will also undergo safety and severity of symptoms assessments. Please call Colleen at (813) 974-9104 to make a referral.

Principal Investigator: Daniel Fallon, MD

#### Investigational Medication (Ecopipam) for Children and Adolescents with Tourette's Disorder

The purpose of this research study is to evaluate an experimental drug called ecopipam in children ages 7 to 17 with Tourette's syndrome. The drug has not been approved by the FDA. There will be eight study visits and six telephone call visits, totally about 4 months. For the first two weeks of the Study Drug Part 1, subject will slowly increase the number of tablets (50/50 placebo or ecopipam) and stay on a stable dose for 2 weeks before discontinuing the study drug. After at least 10 days, subject will be re-examined. Study Drug Part 3 will be very much like Study Drug Part 1: for the first two weeks of the Study Drug Part 3, the subject will slowly increase the number of tablets (50/50 placebo or ecopipam, opposite of part 1) and stay on a stable dose for 2 weeks before discontinuing the study drug. Compensation for time and travel is also available. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

#### T-FORCE Study: Investigational Medication for Children and Adolescents with Tourette's Disorder

The primary purpose of this research study is to determine the safety and tolerability of an investigational medication (NBI-98854) for Tourette syndrome. Each child will be evaluated to determine his or her eligibility to participate in the research study. Each participant who qualifies will receive the investigational medication, study-related medical exams, and laboratory tests at no cost. As some of the medical appointments can be lengthy, many forms of entertainment will be available to participants at his or her study visits. Compensation for time and travel is also available. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

#### Investigational Medication (SD-809 [Deutetrabenazine]) for Adolescents with Tourette's Disorder

The purpose of this research study is to evaluate an investigational medication (SD-809 [Deutetrabenazine]) that may help reduce tics. Tetrabenazine is a drug that has been approved in several European Union countries and Canada for the treatment of various movement disorders including tics, and it has also been approved by the US Food and Drug Administration (FDA) for the treatment of involuntary movements associated with Huntington Disease. SD-809 is an investigational drug, meaning it has not been approved by the FDA. SD-809 has the same action as tetrabenazine; however, SD-809 is broken down in the body more slowly than tetrabenazine. These differences in break down and release may mean that SD-809: 1) may be taken fewer times a day and 2) may react differently in the body compared to tetrabenazine. Study participants must be 12-18 years old and diagnosed with Tourette's Disorder. The clinical trial will involve taking the experimental drug for an 8-week period. Study participants will be compensated for their time. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

#### Investigational Medication (Bitopertin) for Adults with OCD

The purpose of this research study is to evaluate an investigational medication (bitopertin) for adults with OCD, and determine if patients treated with bitopertin and a selective serotonin reuptake inhibitor (SSRI) may experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD. To prequalify for this study, patients must be between the ages of 18 and 65 years, currently taking medication for OCD, and continue to have symptoms of OCD while on medication. Additional eligibility requirements will be discussed with all potential participants prior to enrollment. Reimbursement for travel may also be provided. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

#### Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 6-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

#### Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder

The purpose of this research study is to assess the efficacy of a form of Cognitive Behavioral Therapy (CBT), called Stepped Care CBT, that requires fewer therapy visits and utilizes family members as active components in treatment. Children and families who are interested must complete an initial assessment to determine eligibility.

Eligible participants must be between 8 and 17 years of age and have a primary diagnosis of Obsessive Compulsive Disorder. Once eligibility is determined, participants will be randomly assigned to receive Stepped Care CBT or standard CBT. Those receiving Stepped Care CBT begin treatment in "Step One" which includes 3 sessions with a therapist over the course of 6 weeks while being coached through a take-home workbook. If after 6 weeks it is determined by the research team that insufficient progress has been made, participants progress to "Step Two" which includes 9 additional therapy sessions over 9 weeks. Those receiving standard CBT will receive weekly therapy sessions for 12 weeks. Please contact Brittany Dane at (727) 767-7427 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

#### Parent-led Behavioral Treatment for Young Children with Problematic Anxiety

The purpose of this research study is to examine the effectiveness of a parent-led behavioral treatment for children ages 3 to 7 years old with problematic anxiety. Children and families who are interested must complete an initial assessment to determine eligibility. Once eligibility is determined, participants will be randomly assigned to receive 5 weeks of the parent-led behavioral treatment or a 5 week wait-list condition (followed by 5 weeks of the therapy intervention). Please call (727) 767-8230 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

For more information on current open studies or to refer a patient, please call Kathy 813-974-7006 or Colleen 813-974-9104